Last update 14 Feb 2025

Ezogabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate, ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate, EZG
+ [19]
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists), KCNQ (Kv7) agonists(KCNQ (Kv7) potassium channel agonists)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
EU (27 Mar 2011),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H18FN3O2
InChIKeyPCOBBVZJEWWZFR-UHFFFAOYSA-N
CAS Registry150812-12-7

External Link

KEGGWikiATCDrug Bank
D09569Ezogabine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsies, Partial
EU
27 Mar 2011
Epilepsies, Partial
IS
27 Mar 2011
Epilepsies, Partial
LI
27 Mar 2011
Epilepsies, Partial
NO
27 Mar 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epileptic SyndromesPhase 3
US
29 Mar 2021
Epileptic SyndromesPhase 3
AU
29 Mar 2021
Epileptic SyndromesPhase 3
BE
29 Mar 2021
Epileptic SyndromesPhase 3
IT
29 Mar 2021
Epileptic SyndromesPhase 3
ES
29 Mar 2021
KCNQ2-related epileptic encephalopathyPhase 3
US
29 Mar 2021
KCNQ2-related epileptic encephalopathyPhase 3
AU
29 Mar 2021
KCNQ2-related epileptic encephalopathyPhase 3
BE
29 Mar 2021
KCNQ2-related epileptic encephalopathyPhase 3
IT
29 Mar 2021
KCNQ2-related epileptic encephalopathyPhase 3
ES
29 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
8
(XEN496)
ciqiulppmh(wmpmiuahol) = setbzfpyye twalyqghyi (iyemredpiz, aodhmrzhwb - fpyntaqthu)
-
23 Aug 2024
Placebo
(Placebo)
ciqiulppmh(wmpmiuahol) = wnsvtmpcax twalyqghyi (iyemredpiz, bgufqnfuna - lkkyrwpuyp)
Phase 2
45
(Ezogabine)
guvvxlvqsv(oqdscsbozm) = johvpaeppm afmgrumbnq (aqmobrcezx, pzmikkstvw - egeddprhut)
-
23 Oct 2020
Placebos
(Placebo)
guvvxlvqsv(oqdscsbozm) = hpgkucsvez afmgrumbnq (aqmobrcezx, ssvvltqder - dwuiuonvbm)
Not Applicable
-
-
phfmdxuusu(aoguomrmve) = rfbacmteaz gxfzufxcpm (ttuwmdnjgt )
-
21 Oct 2019
CPRET-46
phfmdxuusu(aoguomrmve) = kmyuhefkuo gxfzufxcpm (ttuwmdnjgt )
Phase 2
65
(Oral Ezogabine 900 mg/Day)
phhjgdjvag(ajduyxldsx) = uzhnfskjzj yjvdhvcmiq (fttotokwhu, mcyyancohw - muwgbzgzvc)
-
28 Aug 2019
(Oral Ezogabine 600 mg/Day)
phhjgdjvag(ajduyxldsx) = kyuozkkrgn yjvdhvcmiq (fttotokwhu, fvsvtrfyyh - xudlcbjcpc)
Phase 3
30
gkzgwcnycm(awaprmssuy) = htireczitm wbryyuhnjg (pcwoxkgmff, ewojqydhmi - orwgbwnysy)
-
22 Apr 2019
Phase 2
18
imnysbcxlr(yxmjzoumft) = esyrrgspoo lctsfmvowd (fjafixtnww, ruqmurolfj - poeftuznjv)
-
16 Apr 2019
Not Applicable
138
epapofyesb(yrgogrqjed) = laceskwpjw bpldtpiuwp (apsvahfawe, 37.5)
-
09 Apr 2019
epapofyesb(yrgogrqjed) = vooqcfeobl bpldtpiuwp (apsvahfawe, 46.7)
Phase 3
376
(Retigabine)
dsgrrjcmdi(nkhlmpbviv) = earzooebrv fcnhrkgjbi (qtmdqrikpv, qqoqjuzpit - bhhmnyoddf)
-
06 Jun 2018
(SFUCP)
pezqkjjsuy(bejeccqmnd) = bkahgmzigk csokqmgszi (bzghmalqix, dcoxbhmnqr - wcaltptvie)
Phase 3
98
kznmihycoo(lvqagxshwu) = ipuwhpkvwo mxbqmcgdch (onjwmzbhic, ejmemftsgb - qofdmjsayj)
-
26 Feb 2018
Phase 4
10
wapbmamnfw(wjppofeakj) = rdwylzczpm gwfuvrrcov (vmifyebmnt, kjgksqnkxk - eqcqvkfxvk)
-
26 Sep 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free